Grzegorz Nowakowski
Seminars
Tuesday 9th March 2027
CEO & ADC Pharma Leaders Think Tank: Solidifying Next-Generation ADCs as Standard of Care Therapies
9:00 am
- Outlining the latest trends across the ADC landscape in 2027 and future vision to develop and deliver novel ADCs with meaningful patient impact with safety and efficacy
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
Wednesday 10th March 2027
Showcasing the Pre-Clinical to Phase I Clinical Development of DS3790 – A Novel CD37 Target & First DXd ADC in Haematology
3:45 pm
- DS3790 is an investigational, potential first-in-class CD37 directed ADC
- Showcasing designs with DXd ADC technology, DS3790 is comprised of a humanized anti-CD37 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (exatecan derivative, DXd) via tetrapeptide-based cleavable linkers
